EHA 2015: Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera - 101793

Spotlight
Video

EHA 2015: Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy's and St Thomas' NHS Foundation Trust, London, UK, provides an update on the ongoing, multicenter, open-label, phase 3 RESPONSE trial, which is comparing the JAK1/2 inhibitor, ruxolitinib, versus best-available therapy in patients with polycythemia vera who are intolerant of or resistant to first-line therapy with hydroxyurea.

—————

The Video Journal of Hematological Oncology (VJHemOnc) is an independent, open-access video journal. In order to improve the awareness and understanding of hematological malignancies, we are dedicated to providing trusted and up-to-date information.

Website: http://www.vjhemonc.com/...
Twitter: https://twitter.com/VJHemOn...
Facebook: https://www.facebook.com/vj...
LinkedIn: https://www.linkedin.com/co...
Shared By : VJHemOnc
Posted on : 07/27/15
Added : 3 years ago